Halozyme Therapeutics, Inc. vs. X4 Pharmaceuticals, Inc. Common Stock
HALO
Halozyme Therapeutics, Inc.
$108.31 -1.71%
VS XFORX4 Pharmaceuticals, Inc. Common Stock
$3.50 -13.24%
X4 Pharmaceuticals, Inc. Common Stock (XFOR) comes out ahead, leading on 2 of 3 compared factors.
Size & Scale
| HALO | XFOR | |
|---|---|---|
| Market Cap | $12.29 billion | $347.51 million |
| Revenue (TTM) | $1.66 billion | — |
| Net Income (TTM) | $413.60 million | — |
HALO leads on 1 of 1 size & scale factors.
Valuation
| HALO | XFOR | |
|---|---|---|
| P/E Ratio | 31.67 | — |
| Price / Book | 85.64 | 2.24 |
| Price / Sales | 7.39 | — |
XFOR leads on 1 of 1 valuation factors.
Profitability
| HALO | XFOR | |
|---|---|---|
| Net Margin | 24.86% | — |
| Return on Equity | 288.13% | — |
HALO and XFOR split the profitability factors evenly.
Risk & Sentiment
| HALO | XFOR | |
|---|---|---|
| Short Interest | 9.79% | 0.08% |
XFOR leads on 1 of 1 risk & sentiment factors.
Dig deeper: HALO overview, HALO financials, XFOR overview, XFOR financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.